Detalhe da pesquisa
1.
Comparative effectiveness of ZUMA-5 (axi-cel) vs SCHOLAR-5 external control in relapsed/refractory follicular lymphoma.
Blood
; 140(8): 851-860, 2022 08 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-35679476
2.
Cost-effectiveness of axicabtagene ciloleucel for adult patients with relapsed or refractory follicular lymphoma in the United States.
Value Health
; 2024 Apr 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-38641058
3.
Treatment patterns and outcomes in relapsed/refractory follicular lymphoma: results from the international SCHOLAR-5 study.
Haematologica
; 108(3): 822-832, 2023 03 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36263843
4.
Clinical outcomes in patients relapsed/refractory after ≥2 prior lines of therapy for follicular lymphoma: a systematic literature review and meta-analysis.
BMC Cancer
; 23(1): 74, 2023 Jan 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-36690960
5.
Burden of illness and outcomes in second-line large B-cell lymphoma treatment: real-world analysis of Medicare beneficiaries.
Future Oncol
; 17(35): 4837-4847, 2021 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-34645318
6.
The impact of pharmacy-based immunization services on the likelihood of immunization in the United States.
J Am Pharm Assoc (2003)
; 58(5): 505-514.e2, 2018.
Artigo
em Inglês
| MEDLINE | ID: mdl-30076098
7.
The validity of the SF-12 and SF-6D instruments in people living with HIV/AIDS in Kenya.
Health Qual Life Outcomes
; 15(1): 143, 2017 Jul 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-28716065
8.
Mobile health for early retention in HIV care: a qualitative study in Kenya (WelTel Retain).
Afr J AIDS Res
; 13(4): 331-8, 2014.
Artigo
em Inglês
| MEDLINE | ID: mdl-25555099
9.
An updated cost-effectiveness analysis of axicabtagene ciloleucel in second-line large B-cell lymphoma patients in the United States.
J Med Econ
; 27(1): 77-83, 2024.
Artigo
em Inglês
| MEDLINE | ID: mdl-38053517
10.
Network meta-analysis of CAR T-Cell therapy for the treatment of 3L+ R/R LBCL after using published comparative studies.
Expert Rev Anticancer Ther
; 24(6): 457-465, 2024 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-38646700
11.
Cost-effectiveness of axicabtagene ciloleucel versus tisagenlecleucel for the treatment of 3L + relapsed/refractory large B-cell lymphoma in the United States: incorporating longer survival results.
J Med Econ
; 27(1): 230-239, 2024.
Artigo
em Inglês
| MEDLINE | ID: mdl-38240256
12.
A Comparison of 3-Year Follow-up of ZUMA-5 (Axicabtagene Ciloleucel) With SCHOLAR-5 in Relapsed/Refractory Follicular Lymphoma.
Clin Lymphoma Myeloma Leuk
; 24(5): e191-e195.e6, 2024 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-38365528
13.
A 24-month updated analysis of the comparative effectiveness of ZUMA-5 (axi-cel) vs. SCHOLAR-5 external control in relapsed/refractory follicular lymphoma.
Expert Rev Anticancer Ther
; 23(2): 199-206, 2023 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-36723678
14.
Approaches to Selecting "Time Zero" in External Control Arms with Multiple Potential Entry Points: A Simulation Study of 8 Approaches.
Med Decis Making
; 42(7): 893-905, 2022 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-35514320
15.
Matching-adjusted indirect comparison of axi-cel and liso-cel in relapsed or refractory large B-cell lymphoma.
Leuk Lymphoma
; 63(13): 3052-3062, 2022 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-36048026
16.
The Cost-Effectiveness of Axicabtagene Ciloleucel as Second-Line Therapy in Patients with Large B-Cell Lymphoma in the United States: An Economic Evaluation of the ZUMA-7 Trial.
Transplant Cell Ther
; 28(11): 750.e1-750.e6, 2022 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-35970302
17.
Economic and Clinical Burden Associated With Intensification of Glaucoma Topical Therapy: A US Claims-based Analysis.
J Glaucoma
; 30(3): 242-250, 2021 03 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33137015
18.
Need for risk adjustment in comparative effectiveness and cost-effectiveness studies in r/r follicular lymphoma.
Blood Adv
; 7(11): 2494-2495, 2023 06 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-36661331
19.
Evaluating Alternative Designs of a Multilevel HIV Intervention in Maharashtra, India: The Impact of Stakeholder Constraints.
MDM Policy Pract
; 3(2): 2381468318803940, 2018.
Artigo
em Inglês
| MEDLINE | ID: mdl-30349875
20.
Burden of non-adherence to latent tuberculosis infection drug therapy and the potential cost-effectiveness of adherence interventions in Canada: a simulation study.
BMJ Open
; 7(9): e015108, 2017 Sep 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-28918407